203/212PbPb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience

Imaging with 203PbPb-VMT-α-NET followed by a single dose of 212PbPb-VMT-α-NET appears to be well tolerated with promising efficacy, even in a heterogenous and heavily pretreated patient population. Further studies are warranted to examine tolerability and efficacy over multiple treatment cycles in larger patient populations.